Cargando…

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis

Guselkumab is an anti‐interleukin‐23 human monoclonal antibody effective in treating psoriatic arthritis (PsA). To characterize the pharmacokinetics (PKs) and exposure‐response relationship of guselkumab in PsA, population PKs, and exposure‐response modeling, analyses were conducted using data from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yang, Miao, Xin, Hsu, Chyi‐Hung, Zhuang, Yanli, Kollmeier, Alexa, Xu, Zhenhua, Zhou, Honghui, Sharma, Amarnath
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932692/ https://www.ncbi.nlm.nih.gov/pubmed/34854241 http://dx.doi.org/10.1111/cts.13197

Ejemplares similares

Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
por: Zhu, Yaowei, et al.
Publicado: (2020)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2021)

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021)

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials
por: Siebert, Stefan, et al.
Publicado: (2023)

Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
por: Schett, Georg, et al.
Publicado: (2022)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
por: Mease, Philip J., et al.
Publicado: (2023)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
por: Schett, Georg, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
por: Thakre, Neha, et al.
Publicado: (2022)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
por: Rahman, Proton, et al.
Publicado: (2021)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
por: Ritchlin, Christopher T, et al.
Publicado: (2022)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
por: Orbai, Ana-Maria, et al.
Publicado: (2023)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
por: McGonagle, Dennis, et al.
Publicado: (2023)

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials
por: Muensterman, Elena, et al.
Publicado: (2021)

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
por: Ritchlin, Christopher T, et al.
Publicado: (2021)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
por: Gottlieb, Alice B, et al.
Publicado: (2023)

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial
por: Helliwell, Philip S., et al.
Publicado: (2020)

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
por: Xie, Rujia, et al.
Publicado: (2019)

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2022)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
por: Sweet, Kristen, et al.
Publicado: (2021)

Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
por: Leu, Jocelyn H., et al.
Publicado: (2022)

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
por: Smolen, Josef S, et al.
Publicado: (2017)

Guselkumab for plaque psoriasis
Publicado: (2019)

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
por: Siebert, Stefan, et al.
Publicado: (2022)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
por: Gladman, Dafna D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nh94hnsqvu1t927p4m557qed29